StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
13
Publishing Date
2022 - 10 - 11
1
2022 - 10 - 06
2
2022 - 09 - 19
1
2022 - 09 - 11
1
2022 - 08 - 30
1
2022 - 07 - 27
1
2022 - 02 - 14
1
2021 - 09 - 28
1
2021 - 04 - 12
1
2021 - 04 - 08
1
2021 - 03 - 10
1
2020 - 12 - 22
1
Sector
Finance
1
Health technology
13
Tags
Acquisition
9
Alliances
7
America
31
Antibody
10
Application
12
Approval
22
Asia
8
Biosimilar
21
Biotech-bay
28
Biotech-beach
13
Cancer
91
Cell
7
Clinical-trials-phase-iii
9
Collaboration
10
Companies
11
Conference
35
Deadline
21
Disease
26
Drug
54
Earnings
9
Eb613
11
Europe
15
Events
15
Expected
10
Fda
23
Financial
25
Financial results
13
Gene therapy
7
Global
83
Growing
15
Growth
102
Health
10
Leukemia
10
Liver
7
Lumakras
15
Lung
7
Lung cancer
16
Market
222
N/a
571
Osteoporosis
11
People
26
Pharma
12
Pharmaceuticals
8
Phase 2
15
Phase 3
7
Positive
14
Potential
9
Psoriasis
12
Reach
8
Report
58
Research
45
Results
53
Risk
9
Set
10
Technology
12
Therapeutics
69
Therapy
42
Treatment
46
Trial
13
Update
8
Entities
Abbvie inc.
1
Amgen inc.
13
Autolus therapeutics plc
1
Beigene, ltd.
6
Bridgebio pharma, inc.
1
Bristol-myers squibb company
1
Chemocentryx, inc.
2
Entera bio ltd.
2
Ideaya biosciences, inc.
1
Johnson & johnson
1
Morgan stanley
1
Novartis ag
2
Sangamo therapeutics, inc.
1
Symbols
ABB
72
ABBV
32
ABLZF
31
ACHV
21
AIMC
23
ALDX
32
ALPMF
22
ALPMY
22
ARQT
22
ARVL
21
ATHE
26
ATNM
25
AVXL
21
AZN
52
BGNE
23
BIVI
23
BMY
48
BTAI
26
CLSD
22
CNHI
69
CYTK
24
DVAX
23
ENLV
25
EXEL
28
FBIO
29
FDMT
21
FNCTF
66
GIC
37
GILD
23
GTES
25
HCM
22
HON
53
HZNP
35
ICLR
26
IMAB
21
IMMP
25
IMMX
23
IMUX
21
INCY
28
JCI
22
JNJ
99
LLY
116
MBRX
30
MRK
45
NVCR
23
NVO
32
NVS
25
OCGN
23
PDSB
23
PFE
47
PSTV
29
REGN
30
RGNX
27
SLS
23
SNY
166
SNYNF
121
SRNE
33
STAG
32
TAK
36
TMO
28
Exchanges
Nasdaq
13
Nyse
4
Crawled Date
2022 - 10 - 11
1
2022 - 10 - 06
2
2022 - 09 - 19
1
2022 - 09 - 12
1
2022 - 08 - 30
1
2022 - 07 - 27
1
2022 - 02 - 14
1
2021 - 09 - 28
1
2021 - 04 - 12
1
2021 - 04 - 08
1
2021 - 03 - 10
1
2020 - 12 - 22
1
Crawled Time
00:00
1
06:00
1
08:07
1
11:00
1
12:00
4
12:39
1
16:00
1
20:00
1
21:00
1
23:00
1
Source
www.biospace.com
5
www.globenewswire.com
3
www.prnewswire.com
5
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Trial
symbols :
Amgn
save search
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
Published:
2022-10-11
(Crawled : 12:00)
- globenewswire.com
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-28.46%
|
O:
0.12%
H:
2.63%
C:
1.59%
BBIO
|
$25.02
-1.73%
-1.76%
1.5M
|
Health Technology
|
145.28%
|
O:
1.06%
H:
3.53%
C:
0.95%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
17.83%
|
O:
3.16%
H:
4.59%
C:
2.48%
bbp-398
lumakras
fda
designation
lung
pharma
trial
cancer
fast track designation
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
Published:
2022-10-06
(Crawled : 12:00)
- globenewswire.com
ENTX
|
$2.07
-6.76%
-7.25%
160K
|
Health Technology
|
111.43%
|
O:
7.62%
H:
0.0%
C:
-7.08%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
16.99%
|
O:
-0.56%
H:
0.27%
C:
-0.68%
eb613
treatment
fda
trial
agreement
osteoporosis
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis- Total Hip BMD Established as Primary Endpoint -
Published:
2022-10-06
(Crawled : 12:00)
- biospace.com/
ENTX
|
$2.07
-6.76%
-7.25%
160K
|
Health Technology
|
111.43%
|
O:
7.62%
H:
0.0%
C:
-7.08%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
16.99%
|
O:
-0.56%
H:
0.27%
C:
-0.68%
eb613
treatment
fda
trial
agreement
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
Published:
2022-09-19
(Crawled : 06:00)
- globenewswire.com
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
22.58%
|
O:
-0.52%
H:
0.69%
C:
0.62%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
18.34%
|
O:
-0.22%
H:
0.1%
C:
0.05%
biosimilar
trial
positive
LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER
Published:
2022-09-11
(Crawled : 00:00)
- prnewswire.com
MS
|
News
0 d
|
$93.85
0.1%
0.0%
4.8M
|
Finance
|
4.81%
|
O:
0.6%
H:
1.16%
C:
0.17%
CCXI
|
News
|
$51.99
-0.04%
|
Health Technology
|
0.85%
|
O:
-0.16%
H:
0.16%
C:
0.06%
BGNE
|
$144.0
3.61%
3.48%
220K
|
Health Technology
|
-18.58%
|
O:
-1.88%
H:
3.78%
C:
3.73%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
10.44%
|
O:
-3.91%
H:
1.55%
C:
-0.16%
lumakras
lung
trial
positive
cancer
AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
Published:
2022-08-30
(Crawled : 21:00)
- prnewswire.com
CCXI
|
News
|
$51.99
-0.04%
|
Health Technology
|
1.78%
|
O:
0.12%
H:
0.16%
C:
-0.31%
BGNE
|
$144.0
3.61%
3.48%
220K
|
Health Technology
|
-16.03%
|
O:
3.3%
H:
1.98%
C:
0.39%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
14.39%
|
O:
1.03%
H:
0.95%
C:
-0.53%
lumakras
lung
topline
trial
cancer
IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors
Published:
2022-07-27
(Crawled : 11:00)
- biospace.com/
IDYA
|
News
|
$39.85
2.13%
2.08%
1.3M
|
Health Technology
|
156.54%
|
O:
1.12%
H:
2.86%
C:
1.89%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
8.92%
|
O:
-0.79%
H:
1.44%
C:
1.03%
collaboration
trial
LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL
Published:
2022-02-14
(Crawled : 23:00)
- prnewswire.com
BGNE
|
$144.0
3.61%
3.48%
220K
|
Health Technology
|
-32.3%
|
O:
4.23%
H:
6.03%
C:
2.76%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
21.97%
|
O:
0.33%
H:
0.52%
C:
-0.47%
lumakras
trial
100
cancer
pancreatic
Global CAR-T Cell Therapy Markets to 2026: Rising Clinical Trials and Development of New and Effective Therapy Options
Published:
2021-09-28
(Crawled : 16:00)
- prnewswire.com
NVSEF
|
News
|
$96.0
6.88%
52K
|
Health Technology
|
17.56%
|
O:
-0.12%
H:
1.77%
C:
-0.99%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
19.7%
|
O:
0.16%
H:
0.04%
C:
-0.51%
JNJ
|
News
|
$148.53
-0.69%
-0.14%
9.6M
|
Health Technology
|
-8.28%
|
O:
-0.04%
H:
0.5%
C:
-0.18%
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
57.39%
|
O:
-0.09%
H:
0.93%
C:
-0.26%
SGMO
|
News
|
$0.4911
-5.72%
-6.07%
1.2M
|
Health Technology
|
-94.69%
|
O:
-1.12%
H:
0.52%
C:
-2.17%
AUTL
|
$4.23
-5.58%
-5.91%
2.7M
|
Health Technology
|
-37.08%
|
O:
-2.67%
H:
1.27%
C:
-5.48%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
28.36%
|
O:
-0.38%
H:
1.16%
C:
-0.01%
clinical trials
therapy
car-t
trials
trial
t-cell
BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021
Published:
2021-04-12
(Crawled : 20:00)
- biospace.com/
BGNE
|
$144.0
3.61%
3.48%
220K
|
Health Technology
|
-54.91%
|
O:
0.09%
H:
0.0%
C:
-4.44%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
9.88%
|
O:
-0.17%
H:
0.6%
C:
0.17%
lung cancer
results
cancer
trial
BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
Published:
2021-04-08
(Crawled : 12:00)
- biospace.com/
BGNE
|
$144.0
3.61%
3.48%
220K
|
Health Technology
|
-56.78%
|
O:
1.06%
H:
0.92%
C:
-3.19%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
10.25%
|
O:
0.39%
H:
0.15%
C:
-0.89%
covid
phase 2
trial
brukinsa
BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025
Published:
2021-03-10
(Crawled : 12:39)
- biospace.com/
BGNE
|
$144.0
3.61%
3.48%
220K
|
Health Technology
|
-55.72%
|
O:
0.98%
H:
0.39%
C:
-3.74%
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
19.45%
|
O:
1.08%
H:
0.88%
C:
-0.65%
phase 1
trial
phase 3
phase 2
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Published:
2020-12-22
(Crawled : 08:07)
- prnewswire.com
AMGN
|
News
|
$273.085
-0.17%
-0.17%
2.5M
|
Health Technology
|
20.34%
|
O:
-0.7%
H:
0.33%
C:
-2.1%
phase 3
trial
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.